For the quarter ending 2025-09-30, RAPT made $21,246,000 in revenue. -$17,496,000 in net income. Net profit margin of -82.35%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Research and development | 12,034,000 | 12,340,000 | 12,042,000 | 31,292,333.333 |
| General and administrative | 7,337,000 | 7,195,000 | 7,223,000 | 7,478,666.667 |
| Total operating expenses | 19,371,000 | 19,535,000 | 19,265,000 | 38,771,000 |
| Loss from operations | -19,371,000 | -19,535,000 | -19,265,000 | -38,771,000 |
| Other income, net | 1,791,000 | 1,892,000 | 2,100,000 | 1,626,666.667 |
| Net loss | -17,580,000 | -17,643,000 | -17,165,000 | -37,144,333.333 |
| Unrealized gain on marketable securities | 84,000 | -19,000 | -15,000 | -69,000 |
| Total comprehensive loss | -17,496,000 | -17,662,000 | -17,180,000 | -37,213,333.333 |
| Net loss per share, basic | -0.65 | -0.65 | -0.08 | -0.907 |
| Net loss per share, diluted | -0.65 | -0.65 | -0.08 | -0.907 |
| Weighted-average shares used to compute net loss per share, basic | 26,963,107 | 26,949,752 | 215,410,253 | 619,222.333 |
| Weighted-average shares used to compute net loss per share, diluted | 26,963,107 | 26,949,752 | 215,410,253 | 619,222.333 |
RAPT Therapeutics, Inc. (RAPT)
RAPT Therapeutics, Inc. (RAPT)